EUVIMEDObjevte EUVIMED
Open access

REDOMA: Bayesian random‐effects dose‐optimization meta‐analysis using spike‐and‐slab priors

Cheng-Han Yang iD, Evan Kwiatkowski, J Jack Lee, Ruitao Lin iD

Statistics in Medicine · 2024

DOI: 10.1002/sim.10107 ↗

At a glance

Journal article in Statistics in Medicine, 2024. Written by Cheng-Han Yang and 3 co-authors. Institution: Department of Biostatistics, The University of Texas Health Science Center at Houston, Houston, Texas, USA. Major MEDLINE topics: Bayes Theorem, Dose-Response Relationship, Drug. 56 references. The full text is freely available in PubMed Central. Funded by: NCI NIH HHS, NIH HHS, National Institutes of Health.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

The rise of cutting‐edge precision cancer treatments has led to a growing significance of the optimal biological dose (OBD) in modern oncology trials. These trials now prioritize the consideration of both toxicity and efficacy simultaneously when determining the most desirable dosage for treatment. Traditional approaches in early‐phase oncology trials have conventionally relied on the assumption of a monotone relationship between treatment efficacy and dosage. However, this assumption may not hold valid for novel oncology therapies. In reality, the dose‐efficacy curve of such treatments may reach a plateau at a specific dose, posing challenges for conventional methods in accurately identifying the OBD. Furthermore, achieving reliable identification of the OBD is typically not possible based on a single small‐sample trial. With data from multiple phase I and phase I/II trials, we propose a novel Bayesian random‐effects dose‐optimization meta‐analysis (REDOMA) approach to identify the OBD by synthesizing toxicity and efficacy data from each trial. The REDOMA method can address trials with heterogeneous characteristics. We adopt a curve‐free approach based on a Gamma process prior to model the average dose‐toxicity relationship. In addition, we utilize a Bayesian model selection framework that uses the spike‐and‐slab prior as an automatic variable selection technique to eliminate monotonic constraints on the dose‐efficacy curve. The good performance of the REDOMA method is confirmed by extensive simulation studies.

Subjects

MeSH terms (MEDLINE)

Bayes TheoremDose-Response Relationship, DrugHumansNeoplasmsMeta-Analysis as TopicComputer SimulationClinical Trials, Phase I as TopicAntineoplastic AgentsClinical Trials, Phase II as TopicModels, Statistical

Author keywords

Bayesian methodsdose optimizationmeta‐analysisphase I/II trialspike‐and‐slab prior

Substances

Antineoplastic Agents

Authors and institutions

  • Department of Biostatistics, The University of Texas Health Science Center at Houston, Houston, Texas, USA.
  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID profiles: Cheng-Han Yang, Ruitao Lin

Funding

  • NCI NIH HHS
  • NIH HHS
  • National Institutes of Health

Cite

APA

Yang, C. H., Kwiatkowski, E., Lee, J. J., & Lin, R. (2024). REDOMA: Bayesian random‐effects dose‐optimization meta‐analysis using spike‐and‐slab priors. Statistics in Medicine. https://doi.org/10.1002/sim.10107

Vancouver

Yang CH, Kwiatkowski E, Lee JJ, Lin R. REDOMA: Bayesian random‐effects dose‐optimization meta‐analysis using spike‐and‐slab priors. Statistics in Medicine. 2024. doi:10.1002/sim.10107

BibTeX
@article{Yang2024,
  author = {Yang, Cheng-Han and Kwiatkowski, Evan and Lee, J Jack and Lin, Ruitao},
  title = {REDOMA: Bayesian random‐effects dose‐optimization meta‐analysis using spike‐and‐slab priors},
  journal = {Statistics in Medicine},
  year = {2024},
  doi = {10.1002/sim.10107}
}
Start for free →